Mater Centre - South Brisbane Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2002
NCT00330499
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

Mater Health Services, QLD, Australia

Active Ingredients

Drugs in Phase 3 Trials (3)

cisplatin (platinol) (1 trial)

hydroxyethyl starch (voluven) (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Transitional Cell (Phase 3)

Urinary Bladder Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3